Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05585229 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 4, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Feb 28, 2025 to Aug 31, 2026
    • Start date changed from estimate of Nov 1, 2023 to Oct 27, 2025
    • Study completion date: Aug 31, 2025 to Aug 31, 2026
    • Site details revised
  2. Primary completion date: Jun 15, 2024 to Feb 28, 2025v3 Show 5 more changesShow less
    • Start date: Jun 15, 2023 to Nov 1, 2023
    • Study completion date: Jun 15, 2024 to Aug 31, 2025
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description expanded, about 1 word
    • Collaborators expanded, about 2 words
  3. Primary and study completion dates: Dec 15, 2023 to Jun 15, 2024
    • Start date: Dec 15, 2022 to Jun 15, 2023
    • Collaborators shortened, about 3 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label pilot trial to assess the safety and feasibility of a novel 8-week psilocybin-assisted psychotherapy intervention to facilitate successful tapering/discontinuation of opioid pain medication in adult patients receiving long-term opioid therapy for chronic pain. Participation will last approximately 8 months and includes one or two psilocybin-assisted therapy sessions. The study will evaluate the incidence and severity of adverse events during and after treatment, the number of participants who drop out of the study for intervention-related reasons, and the self-reported benefits and harms of the intervention.
Trial Details
NCT Number NCT05585229
Lead Sponsor University of British Columbia
Collaborators: Etheridge Foundation
Conditions
(from sponsor)		 Opioid Dependence, Chronic Pain
Related terms Chronic Pain, Opioid-Related Disorders
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov